Logo

ABOS

Acumen Pharmaceuticals, Inc.

ABOS

Acumen Pharmaceuticals, Inc. • NASDAQ
$1.88 ▼ -3.59% (-0.07)
Market Cap $113.88 M
52w High $2.46
52w Low $0.85
Dividend Yield 0%
P/E -0.85
Volume 53.32K
Outstanding Shares 60.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $26.513M ▼ $-26.451M ▲ 0% $-0.44 ▲ $-25.383M ▲
Q2-2025 $0 $41.75M ▲ $-40.95M ▼ 0% $-0.68 ▼ $-39.857M ▼
Q1-2025 $0 $30.37M ▼ $-28.796M ▲ 0% $-0.48 ▲ $-27.728M ▲
Q4-2024 $0 $39.553M ▲ $-37.154M ▼ 0% $-0.62 ▼ $-36.073M ▼
Q3-2024 $0 $32.265M $-29.765M 0% $-0.5 $-28.693M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $126.609M ▼ $142.221M ▼ $49.048M ▼ $93.173M ▼
Q2-2025 $143.369M ▼ $171.897M ▼ $54.82M ▲ $117.077M ▼
Q1-2025 $149.148M ▼ $204.478M ▼ $48.957M ▼ $155.521M ▼
Q4-2024 $171.557M ▼ $238.992M ▼ $57.176M ▲ $181.816M ▼
Q3-2024 $200.343M $266.975M $49.773M $217.202M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-26.451M ▲ $-30.489M ▲ $40.511M ▲ $0 $10.022M ▲ $-30.489M ▲
Q2-2025 $-40.95M ▼ $-31.832M ▲ $38.483M ▲ $0 ▲ $6.651M ▲ $-31.841M ▲
Q1-2025 $-28.796M ▲ $-34.121M ▼ $28.689M ▼ $-36K ▼ $-5.468M ▼ $-34.2M ▼
Q4-2024 $-37.154M ▼ $-27.215M ▼ $29.663M ▲ $-9K ▲ $2.443M ▲ $-27.215M ▼
Q3-2024 $-29.765M $-24.596M $-10.132M $-42K $-34.771M $-24.596M

Five-Year Company Overview

Income Statement

Income Statement Acumen is a classic clinical‑stage biotech: it has no product revenue yet and runs entirely at a loss. Expenses have risen as trials progressed, so operating and net losses have grown again in the most recent year after a period of improvement. All profitability metrics are negative, which is normal at this stage but underscores heavy dependence on future trial success and external funding rather than current business earnings.

Balance Sheet

Balance Sheet The balance sheet shows a small but still solid capital base, with meaningful cash and no heavy use of debt. Equity remains positive but has been shrinking as losses accumulate, and total assets have drifted down from prior peaks. The recent introduction of only modest debt suggests the company is still mostly equity‑funded and not over‑levered, but its financial cushion is clearly being drawn down over time.

Cash Flow

Cash Flow Cash flow is consistently negative, reflecting ongoing R&D spending and operating costs without offsetting revenue. Cash burn has increased alongside the advancing clinical program, and there is no meaningful investment in physical assets, so nearly all outflows are for operations. This pattern is typical for a drug developer at this stage but implies that, unless trial outcomes dramatically change the picture, additional capital raises are likely needed over time to support the pipeline.

Competitive Edge

Competitive Edge Acumen’s competitive edge lies in a differentiated approach to Alzheimer’s disease, focusing on soluble amyloid‑beta oligomers rather than plaques, and early data suggest a potentially cleaner safety profile. Partnerships around subcutaneous delivery and enhanced brain penetration add practical and technological advantages that could matter in real‑world use. That said, the company is small and highly focused on a single main program in a space dominated by very large, well‑funded competitors with approved or late‑stage drugs, so its position is both potentially unique and highly vulnerable to trial outcomes.

Innovation and R&D

Innovation and R&D The company is heavily innovation‑driven, with its lead antibody built around a specific scientific hypothesis about the “toxic initiator” in Alzheimer’s. It is experimenting not just with the drug itself but also with how it is delivered and how patients are identified, using blood‑based biomarkers, subcutaneous formulations, and brain‑delivery partnerships. R&D intensity is high and relatively focused, which can create strong leverage if the science works, but it also concentrates risk in a few key readouts expected over the next several years.

Summary

Acumen is an early‑stage Alzheimer’s drug developer with no revenue, ongoing losses, and steady cash burn, financed mainly by equity. Its value is tied almost entirely to the success of its lead program and related technologies, which offer a scientifically distinct angle and some practical advantages but remain unproven. The financials show a runway that is being consumed as trials advance, while the strategic picture is one of high potential impact balanced by high clinical, regulatory, and funding uncertainty typical of small, single‑asset‑focused biotechs.